Detalles de la búsqueda
1.
Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial.
Clin Chem
; 70(1): 307-318, 2024 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38175595
2.
Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspective.
Strahlenther Onkol
; 200(6): 461-467, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38393398
3.
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol
; 24(1): 77-90, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36493792
4.
Return of individual genomic research results within the PRAEGNANT multicenter registry study.
Breast Cancer Res Treat
; 197(2): 355-368, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36409394
5.
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer.
Breast Cancer Res Treat
; 195(1): 55-64, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35829935
6.
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Lancet Oncol
; 22(8): 1151-1161, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34252375
7.
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Oncologist
; 26(1): e53-e65, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32955138
8.
Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors.
Oncology
; 99(12): 780-789, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34535596
9.
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
Breast Cancer Res
; 22(1): 115, 2020 10 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33109233
10.
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.
Oncologist
; 25(9): e1346-e1354, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32536013
11.
Influence of the New FIGO Classification for Cervical Cancer on Patient Survival: A Retrospective Analysis of 265 Histologically Confirmed Cases with FIGO Stages IA to IIB.
Oncology
; 98(2): 91-97, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31593942
12.
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany.
BMC Cancer
; 20(1): 1091, 2020 Nov 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33176725
13.
Feasibility of a large multi-center translational research project for newly diagnosed breast and ovarian cancer patients with affiliated biobank: the BRandO biology and outcome (BiO)-project.
Arch Gynecol Obstet
; 301(1): 273-281, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31781887
14.
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
Int J Mol Sci
; 21(4)2020 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-32085669
15.
Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
Breast Cancer Res
; 21(1): 142, 2019 12 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31829264
16.
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto.
Breast Cancer Res
; 21(1): 60, 2019 05 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31077239
17.
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
Cancer
; 125(2): 307-316, 2019 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30335191
18.
Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial.
Br J Cancer
; 121(12): 1009-1015, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31728025
19.
Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials.
Ann Surg Oncol
; 26(12): 3892-3901, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31350646
20.
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Lancet Oncol
; 19(4): 497-509, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29501363